LSA
KRTX

L & S Advisors’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

L & S Advisors’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3,000
Closed -$393K – 340
2021
Q4 		$393K Buy
+3,000
New +$388K 0.04% 228
2021
Q2 		– Sell
-2,000
Closed -$240K – 398
2021
Q1 		$240K Buy
+2,000
New +$227K 0.03% 316

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

L & S Advisors's KRTX Position: Q1 2022 in Review

L & S Advisors sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2022, closing a stake of 3,000 shares — an estimated $393K sold.

L & S Advisors first reported a position in KRTX in Q1 2021 and held it in 2 quarters. The position peaked at $393K in Q4 2021. 177 funds tracked by Wall St. Rank hold KRTX as of Q1 2022.

  • L & S Advisors reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • L & S Advisors sold 3,000 Karuna Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $393K.
  • L & S Advisors first reported a position in Karuna Therapeutics, Inc. Common Stock in Q1 2021 and held it in 2 quarters.
  • L & S Advisors's Karuna Therapeutics, Inc. Common Stock position peaked at $393K in Q4 2021.
  • 177 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2022.

Based on L & S Advisors's 13F filing for Q1 2022, filed 11 May 2022.